[Targeted therapy for colorectal cancer through miR-204-5p delivered by nanobody-engineered exosomes: an experimental study]., PMID:40375589
Nanobody-based immunotoxins: A precision tool in the treatment of solid tumors., PMID:40347884
Efficient Tumor-Targeted Photosensitizer Based on Nanobody-Coupled Pyropheophorbide-a for Precise Photodynamic Therapy of Tumors., PMID:40298399
Protein Nanoparticles Simultaneously Displaying TRAIL and EGFR-Binding Ligands Effectively Induce Apoptotic Cancer Cell Death and Overcome EGFR-TKI Resistance in Lung Cancer., PMID:40237189
Publisher Correction: Presence of EGF ligand restricts the binding ability of EgB4 nanobody to EGFR extracellular domain., PMID:40185852
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer., PMID:40136373
The generation of a novel HER2-targeting nano PE25 immunotoxin with superior anti-tumor activity and high productivity., PMID:40086588
Her-2 nanobody modified cisplatin nanoparticles for precise chemotherapy of colon cancer., PMID:39976420
Development of Top-Down Mass Spectrometry Strategies in the Chromatographic Time Scale (LC-TD-MS) for the Extended Characterization of an Anti-EGFR Single-Domain Antibody-Drug Conjugate in Both Reduced and Nonreduced Forms., PMID:39889214
A HER2 Specific Nanobody-Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models., PMID:39860260
Presence of EGF ligand restricts the binding ability of EgB4 nanobody to EGFR extracellular domain., PMID:39827297
Decoupling Individual Host Response and Immune Cell Engager Cytotoxic Potency., PMID:39791371
Correction for van de Water et al., Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects., PMID:39786944
Radiolabeled HER2-targeted molecular probes in breast cancer imaging: current knowledge and future prospective., PMID:39751821
Identification of the Pharmacological Components and Its Targets of Sanghuang by Integration of Nontarget Metabolomics and Network Pharmacology Analysis., PMID:39748251
Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups., PMID:39680709
Nanobodies' duo facilitates ultrasensitive serum HER-2/neu immunoassays via enhanced avidity interactions., PMID:39643321
Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation., PMID:39637990
Editorial Note: Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling., PMID:39630016
Antitumor Activity of a Bispecific Chimera Targeting EGFR and Met in Gefitinib-Resistant Non-Small Cell Lung Cancer., PMID:39586988
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay., PMID:39515883
Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years., PMID:39455963
Programmable Circular Multivalent Nanobody-Targeting Chimeras (mNbTACs) for Multireceptor-Mediated Protein Degradation and Targeted Drug Delivery., PMID:39402961
Bacterial Living Therapeutics with Engineered Protein Secretion Circuits to Eliminate Breast Cancer Cells., PMID:39367855
Correction for van de Water et al., Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects., PMID:39348549
Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics., PMID:39275996
Chemo-Enzymatic Functionalization of Bovine Milk Exosomes with an EGFR Nanobody for Target-specific Drug Delivery., PMID:39192477
Imaging and Monitoring HER2 Expression in Tumors during HER2 Antibody-Drug Conjugate Therapy Utilizing a Radiolabeled Site-Specific Single-Domain Antibody Probe: 68Ga-NODAGA-SNA004-GSC., PMID:39077778
Dual-Targeting of the HER2 Cancer Receptor with an Antibody-Directed Enzyme and a Nanobody-Guided MMAE Prodrug Scaffold., PMID:38945824
Structural insights into the role and targeting of EGFRvIII., PMID:38908376
Comparative study of optical fiber immunosensors based on traditional antibody or nanobody for detecting HER2., PMID:38810383
Emerging paradigms and recent progress in targeting ErbB in cancers., PMID:38797570
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives., PMID:38791529
Non-Invasive Delivery of Negatively Charged Nanobodies by Anodal Iontophoresis: When Electroosmosis Dominates Electromigration., PMID:38675200
Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies., PMID:38554946
Nanobody-mediated targeting of zinc phthalocyanine with polymer micelles as nanocarriers., PMID:38492899
Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer., PMID:38466436
Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial., PMID:38459598
NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy., PMID:38384472
Chimeric nanobody-decorated liposomes by self-assembly., PMID:38374413
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers., PMID:38372053
Multivalent Rhamnose-Modified EGFR-Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies., PMID:38286668
Erratum: Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging: Erratum., PMID:38250047
An Albumin-Holliday Junction Biomolecular Modular Design for Programmable Multifunctionality and Prolonged Circulation., PMID:38231391
Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer., PMID:38184235
Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics., PMID:38067344
An off-the-shelf small extracellular vesicle nanomedicine for tumor targeting therapy., PMID:37967724
A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells., PMID:37954614
Insulin-like Growth Factor 2 (IGF2)-Fused Lysosomal Targeting Chimeras for Degradation of Extracellular and Membrane Proteins., PMID:37899626
Penetration of Nanobody-Dextran Polymer Conjugates through Tumor Spheroids., PMID:37896133
For research use only. Not for human or drug use.
